Slide 1: UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy
Place video here UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study) S. Mailankody1, J.V. Matous2, M. Liedtke 3, S. Sidana4, O.O. Oluwole5, M. Meera6, J.C. Cruz7, R. Nath8, F. Anwer9, A. Rossi 10, M. Htut11
Slide 2: The First Allogeneic anti-BCMA CAR T Study for R/R Multiple Myeloma
The First Allogeneic anti-BCMA CAR T Study for R/R Multiple Myeloma Place video here • BCMA autologous chimeric antigen receptor (CAR) T cell therapy has demonstrated unprecedented efficacy, but is not readily available to all patients Human Anti-BCMA scFv • Allogeneic CAR T cell therapy has the pot
Slide 3: UNIVERSAL: First Allogeneic BCMA CAR T in Multiple Myeloma
UNIVERSAL: First Allogeneic BCMA CAR T in Multiple Myeloma Place video here Phase 1, Open-label, Multicenter Dose Escalation Study Enrolling in Thirteen US Centers Key Eligibility Criteria • Relapsed/Refractory Multiple Myeloma • ≥ 3 prior therapies including IMiD, proteasome inhibitor & anti-CD38 •
Slide 4: Patient Demographics of DL3 Expansion
Patient Demographics of DL3 Expansion Place video here Table 1. Patient Demographics, Disease Status, and Prior Therapies in DL3 Expansion DL3 (320 x 106 CAR+ T Cells) FCA39 FCA60 N=28 (n=11) (n=17) Age, median (range), yrs 65 (49, 78) 66 (57, 77) 65 (49, 78) Gender: Male / Female, % 64 / 36 64 / 36
Slide 5: ALLO-715 and ALLO-647 Demonstrated Manageable Safety Profile
ALLO-715 and ALLO-647 Demonstrated Place video here Manageable Safety Profile Table 2. Adverse Events of Special Interest (Safety Analysis Set) All Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 TEAE of Interest* (N=54) Grades n (%) n (%) n (%) n (%) n (%) n (%) • Manageable safety profile with Cytokine Re
Slide 6: Efficacy of ALLO-715 and ALLO-647
Efficacy of ALLO-715 and ALLO-647* Response Rates in Expansion Cohorts Place video here Table 3. Responses in Efficacy Evaluable Patients Followed ≥3 Months Cell Dose DL3 (320M CAR+ T Cells) LD Regimen FCA39 FCA60 Total (n=11) (n=12) (n=23) • Median follow-up for efficacy ORR,* n (%) 7 (64) 8 (67) 1
Slide 7: Tumor Response to Study Treatment for DL3 Expansion Cohorts
Tumor Response to Study Treatment for DL3 Expansion Cohorts Place video here Figure 2. Swimmer Plot of Tumor Response to Study Treatment * DL3 FCA60 * Dose level 3 CAR+ T cell dose * * achieved durable responses in * patients with R/R MM: • In the DL3 FCA60 efficacy evaluable set, the median DOR was
Slide 8: Summary
Summary October 16, 2020 These results demonstrate feasibility of “off the shelf” CAR T in Multiple Myeloma Place video here • 92% of enrolled patients received product with 100% of infused product manufactured and released as per product specifications • Median time from enrollment to LD was 5 days
Slide 9: Thank You
Place video here THANK YOU To Patients, their families and caregivers, Clinical Trial Investigators and Sites ALLO-715 (BCMA) utilizes TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at th